Stock Events

Stock Events

Ultragenyx Pharmaceutical 

€14.02
52
-€0.58-3.97%Friday 16:30

Statistics

Day High
14.03
Day Low
13.59
52W High
15.43
52W Low
13
Volume
33
Avg. Volume
-
Mkt Cap
1.38B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Nov 3Expected
Q2 2026
Q3 2026
-1.06
-0.96
-0.87
-0.78
Expected EPS
-0.981553232
Actual EPS
-1.0347199999999999

Financials

-85.85%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
582.92MRevenue
-500.44MNet Income

Analyst Ratings

$19.86Average Price Target
The highest estimate is ⁦30.35⁩.
From 18 ratings within the last 6 months. This is not an investment recommendation.
Buy
50%
Hold
50%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow UP0.XETRA. It's not an investment recommendation.
Amazon
12
AMZN
NVIDIA
12
NVDA
Apple
11
AAPL
Microsoft
10
MSFT

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap141.65B
Vertex Pharmaceuticals is a competitor because it also focuses on developing treatments for genetic diseases, similar to Ultragenyx's focus on rare genetic disorders.
Biomarin Pharmaceutical
BMRN
Mkt Cap11.33B
BioMarin Pharmaceutical competes directly with Ultragenyx in the rare disease space, particularly in developing enzyme replacement therapies.
Regeneron Pharmaceuticals
REGN
Mkt Cap95.99B
Regeneron Pharmaceuticals is involved in developing treatments for rare diseases among other areas, making it a competitor.
Novo Nordisk
NVO
Mkt Cap176.43B
Novo Nordisk is a leading company in diabetes care but also ventures into treatments for rare blood disorders, competing with Ultragenyx.
Gilead Sciences
GILD
Mkt Cap211.7B
Gilead Sciences, known for its work in antiviral drugs, also has a portfolio in other areas including rare diseases, making it a competitor.
AMGEN
AMGN
Mkt Cap251.94B
Amgen has a broad focus on biologics in various therapeutic areas, including rare diseases, competing with Ultragenyx in this niche.
Pfizer
PFE
Mkt Cap173.95B
Pfizer has a diversified portfolio that includes treatments for rare diseases, making it a competitor to Ultragenyx.
Biogen
BIIB
Mkt Cap37.49B
Biogen focuses on neurological diseases, including some rare conditions, positioning it as a competitor in the rare disease market.

About

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.
Show More
CEO
Emil D. Kakkis
Employees
1371
Country
United States
ISIN
US90400D1081
WKN
000A1XCY0

Listings

STU
DE
UP0.STU
SA
BR
R2AR34.SA
LSE
GB
0LIF.LSE
F
DE
UP0.F

0 Comments

Share your thoughts

FAQs

What is Ultragenyx Pharmaceutical stock price today?▼
The current price of UP0.XETRA is €14.02 EUR — it has decreased by -3.97% in the past 24 hours. Watch Ultragenyx Pharmaceutical stock price performance more closely on the chart.
What is Ultragenyx Pharmaceutical stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XETRA Stock Exchange exchange Ultragenyx Pharmaceutical stocks are traded under the ticker UP0.XETRA.
What is Ultragenyx Pharmaceutical market cap?▼
Today Ultragenyx Pharmaceutical has the market capitalization of 1.38B
When is the next Ultragenyx Pharmaceutical earnings date?▼
Ultragenyx Pharmaceutical is going to release the next earnings report on February 18, 2027.
What were Ultragenyx Pharmaceutical earnings last quarter?▼
UP0.XETRA earnings for the last quarter are -1.03 EUR per share, whereas the estimation was -0.98 EUR resulting in a -5.42% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Ultragenyx Pharmaceutical revenue for the last year?▼
Ultragenyx Pharmaceutical revenue for the last year amounts to 582.92M EUR.
What is Ultragenyx Pharmaceutical net income for the last year?▼
UP0.XETRA net income for the last year is -500.44M EUR.
How many employees does Ultragenyx Pharmaceutical have?▼
As of November 8, 2026, the company has 1,371 employees.
In which sector is Ultragenyx Pharmaceutical located?▼
Ultragenyx Pharmaceutical operates in the Health & Wellness sector.
When did Ultragenyx Pharmaceutical complete a stock split?▼
Ultragenyx Pharmaceutical has not had any recent stock splits.
Where is Ultragenyx Pharmaceutical headquartered?▼
Ultragenyx Pharmaceutical is headquartered in NOVATO, United States.